Dana M. Chase, MD
Accepting new patients

Dana M. Chase, MD

(she/her)
  • Gynecologic Oncology
OBGYN Oncology | 100 Medical Plaza, Suite 383, Los Angeles, CA 90095

About

Dr. Chase is an associate professor of UCLA Obstetrics and Gynecology in the Division of Gynecologic Oncology. She completed her medical degree, residency in obstetrics and gynecology and gynecologic oncology fellowship at the University of California, Irvine.  Her clinical and research interests include clinical trials, chemotherapy, quality of life, the microbiome, health disparities, and geriatric oncology. Dr. Chase is a board-certified gynecologic cancer physician and surgeon.

Languages

English, Spanish

Education

Medical Board Certifications

Gynecologic Oncology, American Board of Obstetrics and Gynecology, 2014
Obstetrics and Gynecology, American Board of Obstetrics and Gynecology, 2009

Fellowship

Gynecologic Oncology, UC Irvine School of Medicine, 2011

Residency

Obstetrics and Gynecology, UC Irvine School of Medicine, 2007

Degree

MD, UC Irvine School of Medicine, 2003

Recognitions

  • Honor Health Physician Recognition Award for Patient Experience, 2022
  • Top Doctor, Phoenix Magazine, 2022, 2021
  • Overall Provider Award, Rating Silver with Near Perfect Score of 90-96, Dignity Health Medical Group, 2016
  • See More

Locations

West Los Angeles

OBGYN Oncology

Obstetrics and Gynecology| Gynecologic Medical Oncology| Cancer Genetics +2 more specialties

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Research

Interests

  • Clinical Trials in Gynecologic Cancers
  • Quality of life/Patient-reported Outcomes
  • Survivorship and symptom management in gynecologic cancers

Publications

  1. Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022 Sep;166(3):494-502. doi: 10.1016/j.ygyno.2022.06.028. Epub 2022 Jul 15. PMID: 35851489.
  2. Chase DM, Neighbors J, Perhanidis J, Monk BJ. Gastrointestinal symptoms and diagnosis preceding ovarian cancer diagnosis: Effects on treatment allocation and potential diagnostic delay. Gynecol Oncol. 2021 Jun;161(3):832-837. doi: 10.1016/j.ygyno.2021.03.021. Epub 2021 Apr 1. PMID: 33814195.
  3. Chase DM, Salani R, Farley J, Torres T, Stone J. Unwittingly biased: A note to gynecologic cancer providers. Gynecol Oncol. 2021 Mar;160(3):646-648. doi: 10.1016/j.ygyno.2021.01.009. Epub 2021 Jan 20. PMID: 33485640.
  4. Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 May;30(5):596-601. doi: 10.1136/ijgc-2019-000869. Epub 2020 Feb 28. Erratum in: Int J Gynecol Cancer. 2020 Aug;30(8):1267. PMID: 32114513; PMCID: PMC7780262.
  5. Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM, Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019 May 14
  6. Chase DM, Huang H, Foss CD, Wenzel LB, Monk BJ, Burger RA. Neurotoxicity in Ovarian Cancer Patients on Gynecologic Oncology Group (GOG) Protocol 218:  Characteristics Associated with Toxicity and the Effect of Substitution with Docetaxel:  An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Feb;136(2):323-7
  7. Chase DM, Kauderer J, Wenzel L, Ramondetta L, Cella D, Long HJ 3rd, Monk BJ. Factors Associated With Grade 3 or 4 Treatment-Related Toxicity in Women With Advanced or Recurrent Cervical Cancer: An Exploratory Analysis of NRG Oncology/Gynecologic Oncology Group Trials 179 and 204. Int J Gynecol Cancer. 2015 Feb;25(2):303-8.
  8. Chase DM Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 2012 Sep;126(3):375-80.
  9. Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR.   Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma.  Gynecol Oncol. 2009 Dec;115(3):339-42.
  10. Chase DM, Lopez S, Nguyen C, et al. A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology? American journal of obstetrics and gynecology.  Am J Obstet Gynecol. 2008 Nov;199(5):541.e1-7
  11. Chase DM, Crade M, Basu T, Saffari B, Berman ML.  Preoperative diagnosis of ovarian malignancy: preliminary results of the use of 3-dimensional vascular ultrasound.  Int J Gynecol Cancer. 2009 Apr;19(3):354-60.

Insurance

  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • L.A. Care
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • TRICARE
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.

Recognitions

  • Honor Health Physician Recognition Award for Patient Experience, 2022
  • Top Doctor, Phoenix Magazine, 2022, 2021
  • Overall Provider Award, Rating Silver with Near Perfect Score of 90-96, Dignity Health Medical Group, 2016
  • St. Joseph’s Hospital Teacher of the Year Award for Obstetrics and Gynecology, Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 2016
  • American Association of Obstetricians and Gynecologists Foundation (AAOGF) and the American Gynecological and Obstetrical Society (AGOS), 2015 AGOS Annual Meeting, Half Moon Bay, CA, 2015
  • Vitals Top 10 Doctor Award, Obstetrics and Gynecology, American Registry, Delray Beach, FL, 2013
  • Young Doctor Summit Award, 14th Biennial International Gynecologic Cancer Society, 2012
  • Oncology Trainee Travel Award, The Conquer Cancer Foundation of ASCO, 2011
  • ASCO Cancer Foundation Merit Award, 2009